Drug Profile
Tofersen - Biogen/Ionis Pharmaceuticals
Alternative Names: BIIB 067; IONIS SOD1Rx; ISIS-333611; ISIS-SOD1Rx; QalsodyLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Center for Neurologic Study; Isis Pharmaceuticals; Ludwig Institute for Cancer Research
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference; Superoxide dismutase 1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amyotrophic lateral sclerosis
Most Recent Events
- 19 Mar 2024 Biogen anticipates Marketing Authorization Application approval for Tofersen in Amyotrophic lateral sclerosis in European Union in the second quarter of 2024
- 19 Mar 2024 Preregistration for Amyotrophic lateral sclerosis in Canada (Intrathecal)
- 19 Mar 2024 Biogen anticipates NDA approval for Tofersen in Amyotrophic lateral sclerosis from Health Canada in early 2025